Axsome Therapeutics (AXSM) stock has been drawing attention after a period of strong share price moves, including gains over the past month and past 3 months. This has prompted investors to reassess its current valuation and risk profile.

Beyond the recent rally, Axsome Therapeutics has seen its 30 day share price return of 27.47% build on a 90 day share price return of 43.07%. The 1 year total shareholder return of 122.97% and 5 year total shareholder return of 282.39% point to strong long term momentum.

If you are watching Axsome for growth in healthcare, it can also be worth scanning other opportunities in the sector, including 37 healthcare AI stocks

With Axsome Therapeutics trading at $234.48, an intrinsic value estimate that sits at a 70.52% discount and a price target of $270.28, the key question is whether there is still an opportunity for investors or if the market is already pricing in future growth.

Most Popular Narrative: 12.2% Undervalued

Against the last close at $234.48, the most followed narrative pegs Axsome Therapeutics' fair value at $266.94, framing the recent share price strength in the context of long term earnings and revenue assumptions.

The company is advancing multiple late-stage clinical programs (AXS-05, AXS-12, AXS-14, and several solriamfetol indications), which positions Axsome to benefit from the aging population and rising prevalence of CNS disorders, potentially resulting in a diversified revenue base, higher earnings, and reduced risk of overreliance on a single product.

Curious what has to happen for that higher fair value to hold up? The narrative leans on steep revenue expansion, a sharp turn into profitability, and a richer future earnings multiple that outpaces the wider pharmaceuticals group.

Result: Fair Value of $266.94 (UNDERVALUED)

However, you also need to factor in execution risk around launches like SYMBRAVO and the company’s ongoing net loss of $188.3 million, which could pressure dilution and delay the positive narrative.

Another Angle On Valuation

There is a twist when you switch from cash flow models to simple sales-based pricing. Axsome trades on a P/S of 17x, while the US pharmaceuticals group sits at 6.4x and direct peers at 4.2x, with a fair ratio of 15.7x suggesting less room for error if growth stumbles.

Next Steps

Given the mixed signals on valuation and sentiment, it makes sense to scan the numbers yourself and decide how comfortable you are with the trade off. To see what is driving the current optimism and to pressure test your own view, start with the 2 key rewards

Looking for more investment ideas?

If Axsome has sharpened your interest, do not stop here. Use focused stock lists to uncover fresh ideas that match your risk, income, and quality preferences.

• Target potential mispricings by scanning 46 high quality undervalued stocks for companies that combine quality traits with lower market expectations.
• Strengthen your income stream by checking 10 dividend fortresses featuring higher yield opportunities that still pay attention to resilience.
• Prioritise capital preservation by reviewing 62 resilient stocks with low risk scores that score well on financial stability and downside protection.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.